Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Microbot Medical Inc.

www.microbotmedical.com

Latest From Microbot Medical Inc.

Deals Shaping The Medical Industry, February 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2018.

Deals Medical Device

Deals Shaping The Medical Industry, July 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2017.

Deals BioPharmaceutical

Stem Cell Data Boosts Asterias In Untapped Spinal Injury Space

Motor function in severe spinal injury patients continues to improve six to nine months after administration of Asterias Biotherapeutics’ stem cell treatment in the Phase I/IIa SCiStar study. The company is figuring out its next steps, including in Japan where the path to market is clearer.

Clinical Trials Research and Development Strategies

StemCells Finds White Knight In Microbot

In May 2016, results from StemCell Inc.’s Phase II study of its only product still in development, a preparation of human neural stem cells for the treatment of chronic spinal cord injuries, suggested that there was little chance of the product ever becoming a commercial success. The company’s stock plummeted 80% overnight. Then, in August, when all appeared to be lost, StemCells announced that it was entering a strategic merger agreement with the Israeli company Microbot Medical Ltd., which researches and develops micro-robotic assisted medical technologies.

Medical Device Business Strategies
See All

Company Information

  • Industry
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Gastrointestinal
  • Gynecological, Urological
  • Neurology, Nervous System
  • Respiratory, Pulmonary
  • Alias(es)
  • StemCells Inc.
  • CytoTherapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Microbot Medical Inc.
  • Senior Management
  • Harel Gadot, Pres., CEO & Chmn.
    David Ben Naim, CFO
    Simon Sharon, CTO
    Hezi Himelfarb, COO
  • Contact Info
  • Microbot Medical Inc.
    Phone: (212) 850-6020
    25 Recreation Park Dr.
    Unit 108
    Hingham, MA 02043
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register